Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

키워드

참고문헌 (56)

1. Paik JM, "Changes in the global burden of chronic liver diseases from 2012 to 2017 : the growing impact of NAFLD", Hepatology, 72, pp.1605~1616 (2020)
2. Yip TC, "Geographical similarity and differences in the burden and genetic predisposition of NAFLD", Hepatology (2022)[DOI]
3. Brunt EM, "Nonalcoholic fatty liver disease", Nat Rev Dis Primers, 1, pp.15080~ (2015)
4. Pirola CJ, "The lipidome in nonalcoholic fatty liver disease : actionable targets", J Lipid Res, 62, pp.100073~ (2021)
5. Sookoian S, "Genetic predisposition in nonalcoholic fatty liver disease", Clin Mol Hepatol, 23, pp.1~12 (2017)
6. Sookoian S, "Genetics of nonalcoholic fatty liver disease : from pathogenesis to therapeutics", Semin Liver Dis, 39, pp.124~140 (2019)
7. Sookoian S, "Genetic pathways in nonalcoholic fatty liver disease : insights from systems biology", Hepatology, 72, pp.330~346 (2020)
8. Carlos J. Pirola, "Personalized medicine in nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 28(4), pp.935~938 (2022), 대한간학회
9. Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
10. Speliotes EK, "Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits", PLoS Genet, 7, pp.e1001324~ (2011)
11. Kozlitina J, "Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 46, pp.352~356 (2014)
12. Abul-Husn NS, "A protein-truncating HSD17B13 variant and protection from chronic liver disease", N Engl J Med, 378, pp.1096~1106 (2018)
13. Salatino A, "Computational pipeline for next-generation sequencing(NGS)studies in genetics of NASH", Methods Mol Biol, 2455, pp.203~222 (2022)
14. Sookoian S, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3gene(PNPLA3)on the susceptibility and histological severity of nonalcoholic fatty liver disease", Hepatology, 53, pp.1883~1894 (2011)
15. Sookoian S, "A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity", J Lipid Res, 50, pp.2111~2116 (2009)
16. Dongiovanni P, "Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease", Hepatology, 61, pp.506~514 (2015)
17. Sookoian S, "Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity", Hepatology, 61, pp.515~525 (2015)
18. Pirola CJ, "The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver : a meta-analysis", Hepatology, 62, pp.1742~1756 (2015)
19. Pirola CJ, "Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease", J Lipid Res, 60, pp.176~185 (2019)
20. Ma Y, "17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease", Hepatology, 69, pp.1504~1519 (2019)
21. Zain SM, "Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease : a meta-analysis", J Gastroenterol Hepatol, 30, pp.21~27 (2015)
22. Teo K, "rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD : a meta-analysis", J Hepatol, 74, pp.20~30 (2021)
23. Baselli GA, "Rare ATG7 genetic variants predispose patients to severe fatty liver disease", J Hepatol, 77, pp.596~606 (2022)
24. Pirola CJ, "A rare nonsense mutation in the glucokinase regulator gene is associated with a rapidly progressive clinical form of nonalcoholic steatohepatitis", Hepatol Commun, 2, pp.1030~1036 (2018)
25. Pirola CJ, "Liver mitochondrial DNA damage and genetic variability of Cytochrome b-a key component of the respirasome-drive the severity of fatty liver disease", J Intern Med, 289, pp.84~96 (2021)
26. Sookoian S, "Mitochondrial genome architecture in non-alcoholic fatty liver disease", J Pathol, 240, pp.437~449 (2016)
27. Sookoian S, "Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease", Oncotarget, 8, pp.22917~22926 (2017)
28. Sookoian S, "Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage", Hepatol Commun, 2, pp.654~665 (2018)
29. Anstee QM, "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort", J Hepatol, 73, pp.505~515 (2020)
30. Vilar-Gomez E, "Impact of the association between PNPLA3 genetic variation and dietary intake on the risk of significant fibrosis in patients with NAFLD", Am J Gastroenterol, 116, pp.994~1006 (2021)
31. Vilar-Gomez E, "The protection conferred by HSD17B13 rs72613567 polymorphism on risk of steatohepatitis and fibrosis may be limited to selected subgroups of patients with NAFLD", Clin Transl Gastroenterol, 12, pp.e00400~ (2021)
32. Vilar-Gomez E, "PNPLA3 rs738409 and risk of fibrosis in NAFLD : exploring mediation pathways through intermediate histological features", Hepatology, 76, pp.1482~1494 (2022)
33. Pirola CJ, "The influence of host genetics on liver microbiome composition in patients with NAFLD", EBioMedicine, 76, pp.103858~ (2022)
34. Fontaine JF, "Génie : literature-based gene prioritization at multi genomic scale", Nucleic Acids Res, 39(Web Server issue), pp.W455~W461 (2011)
35. Wiel C, "BACH1 stabilization by antioxidants stimulates lung cancer metastasis", Cell, 178, pp.330~345 (2019)
36. Wang H, "miR-550a-3", NFIC plays a driving role in esophageal squamous cell cancer cells proliferation and metastasis partly through EMT process, 2020, pp.472, 115~123
37. Park J, "IL-6", STAT3 axis dictates the PNPLA3-mediated susceptibility to nonalcoholic fatty liver disease, 2023, pp.78, 45~56
38. Gianotti TF, "Study of genetic variation in the STAT3 on obesity and insulin resistance in male adults", Obesity(Silver Spring), 16, pp.1702~1707 (2008)
39. Hwangbo H, "Auranofin attenuates non-alcoholic fatty liver disease by suppressing lipid accumulation and NLRP3 inflammasome-mediated hepatic inflammation in vivo and in vitro", Antioxidants(Basel), 9, pp.1040~ (2020)
40. 이승민, "Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways", Clinical and Molecular Hepatology, 28(4), pp.827~840 (2022), 대한간학회
41. Huby T, "Immune cell-mediated features of nonalcoholic steatohepatitis", Nat Rev Immunol, 22, pp.429~443 (2022)
42. Pirola CJ, "Pleiotropy within gene variants associated with nonalcoholic fatty liver disease and traits of the hematopoietic system", World J Gastroenterol, 27, pp.305~320 (2021)
43. Paré G, "Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci", PLoS Genet, 7, pp.e1001374~ (2011)
44. Sookoian S, "Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease", Atherosclerosis, 209, pp.585~591 (2010)
45. Kamat MA, "PhenoScanner V2 : an expanded tool for searching human genotype-phenotype associations", Bioinformatics, 35, pp.4851~4853 (2019)
46. Staley JR, "PhenoScanner : a database of human genotype-phenotype associations", Bioinformatics, 32, pp.3207~3209 (2016)
47. Ott C, "Sam50 functions in mitochondrial intermembrane space bridging and biogenesis of respiratory complexes", Mol Cell Biol, 32, pp.1173~1188 (2012)
48. Batlle E, "Transforming growth factor-β signaling in immunity and cancer", Immunity, 50, pp.924~940 (2019)
49. Schmiedel BJ, "Impact of genetic polymorphisms on human immune cell gene expression", Cell, 175, pp.1701~1715 (2018)
50. Domínguez Conde C, "Cross-tissue immune cell analysis reveals tissuespecific features in humans", Science, 376, pp.eabl5197~ (2022)
51. Dae Won Jun, "An analysis of polygenic risk scores for non-alcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.446~447 (2021), 대한간학회[DOI]
52. Silvia Sookoian, "Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology", Clinical and Molecular Hepatology, 26(4), pp.461~475 (2020), 대한간학회[DOI]
53. Hwi Young Kim, "Recent advances in nonalcoholic fatty liver disease metabolomics", Clinical and Molecular Hepatology, 27(4), pp.553~559 (2021), 대한간학회[DOI]
54. Sookoian S, "Repurposing drugs to target nonalcoholic steatohepatitis", World J Gastroenterol, 25, pp.1783~1796 (2019)
55. Fonseka P, "FunRich enables enrichment analysis of OMICs datasets", J Mol Biol, 433, pp.166747~ (2021)
56. Pathan M, "FunRich : an open access standalone functional enrichment and interaction network analysis tool", Proteomics, 15, pp.2597~2601 (2015)